The pooled results from three studies (47, 25; and our study), including a total of 572 patients with ALS and 321 controls (Supplementary Table 5), did not show any differences in serum C3 levels between patients with ALS and controls (Figure 2B). This evidence concerns the gene C3 and amyotrophic lateral sclerosis.